ArticleGels (Basel, Switzerland)2025
Engineering Moxifloxacin-Encapsulated Liposome-Enriched Alginate Hydrogel Films.
Article in Gels (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Enzyme-Loaded Liposomal Edible Hydrogel Films to Enhance Lactase Activity in Perline Mozzarella.Gels (Basel, Switzerland) · 2026Article
- Advancing transdermal drug delivery through 4D bioprinting and dynamic skin modelling.Frontiers in drug delivery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, we developed a moxifloxacin (MXF)-encapsulated liposome-enriched alginate nanocomposite hydrogel coating. MXF was encapsulated in soy lecithin (SL:MXF:2:1) via the probe sonication method with an average efficiency of 80%. Two different manufacturing methods, including a micropipetting and a T-shaped microfluidic junction (TMJ) device technique, were used to incorporate the MXF-encapsulated liposomes into hydrogel matrices and layered as a coating on polymeric substrate material. Drug encapsulation and its incorporation into the hydrogel matrix significantly enhanced its stability and facilitated a prolonged drug release profile. A relatively rapid drug release was observed in the MXF-encapsulated liposome-loaded polymeric particulate layer developed via the micropipetting than the TMJ device technique. The findings confirmed sustained drug release behavior due to a hydrogel particulate structural uniformity conferred by the micromachine device, TMJ. Thus, these nanocomposite hydrogel coatings achieved can serve as a promising candidate for the treatment of ophthalmic or mucosal membrane infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.